MSDx Presents Poster at the 69th American Academy of Neurology Annual Meeting

MSDx Presents Poster at the 69th American Academy of
Neurology Annual Meeting April 22-28, 2017


Published date April 21, 2017

Press Release

Tucson-Based MSDx, Inc. presented a poster at the 69th American Academy of Neurology (AAN) Annual Meeting April 22-28, 2017 at the Boston Convention Center, Boston, Massachusetts. MSDx Director of Research, Ramesh Nayak, Ph.D. presented research results on a blood-based biomarker for evaluating therapeutic response in multiple sclerosis (MS) patients.

Click here to view or download the article

Re-circulating Phagocytes Loaded with CNS Debris: A Potential Marker of Neurodegeneration in Parkinson’s Disease

AIMS Medical Science Research Article


Published date 15 February 2015

Re-circulating Phagocytes Loaded with CNS Debris: A Potential
Marker of Neurodegeneration in Parkinson’s Disease?

By: Vanessa J. White and Ramesh C. Nayak

Abstract: Diagnosis and monitoring of diseases by measurement of biochemical markers has most commonly been performed on samples of peripheral blood. However, no such markers are available for clinical use in the major diseases of the central nervous system (CNS). In Parkinson’s disease circulating biomarkers would find clinical utility in early diagnosis and also monitoring of disease progression. Of particular interest is early diagnosis as this would create .a window of opportunity for treatment with neuroprotective drugs. We have developed a novel strategy for monitoring disease activity in the CNS based on the recognition that tissue injuries incite inflammation and recruitment of phagocytes that engulf debris.

Click here to view or download the article

MSDx: A Novel Approach for CNS Biomarkers

MSDx Biomarkers for CNS Disease

By: Ramesh C. Nayak

Blood Based Biochemical Monitoring of Major Diseases of the CNS
In the vast majority of diseases of the CNS there are no blood tests to aid in the diagnosis and long-term management of patients. Consequently, there is a pressing clinical need for inexpensive blood tests that allow the physician to closely monitor the physiological status of patients with CNS disease/injury and their response to disease-modifying therapies. To produce tests that provide critical and timely information requires biomarkers that are involved in the disease mechanism. That requires an understanding of how the disease process evolves over time so that key processes can be monitored.

Click here to view or download the paper.

A Team With Expertise

The MSDx team has the necessary scientific and industry expertise, and the flexibility, commitment, and passion needed to navigate the challenges and build a successful company. The company has a talented operating team, an involved board, and a thought-leading Clinical Advisory group.